ClavystBio

Oversees digital health and medtech ventures, previously Managing Director and Head of Venture Capital at Heritas Capital and Partner at Philips Ventures. Holds a BEng from NTU and is a Fellow Chartered and Certified Accountant.

Leads therapeutics investing and venture building, having previously headed Singapore investments and operations for Lightstone Ventures. Holds a PhD in Immunology from Stanford.

Works on medtech investment and venture building, with experience across R&D, ventures and operations at A*STAR, Singapore EDB and Applied Materials. Holds a PhD in Biomedical Engineering from Caltech.

Brings commercial and public sector experience to therapeutics investing and venture building, previously at Lightstone Ventures and as Deputy Director at Singapore's National Research Foundation. Holds a PhD in Biochemistry.

Leads the fund's communications strategy, working with the policy and investment teams. He previously served as senior media relations manager and senior science writer at the Harvard T.H. Chan School of Public Health and worked for Partners In Health.

Portfolio Manager for InnoVenture Iowa's public co-investment fund, working with portfolio-company boards and founders on follow-on strategy. She has over 20 years of operations and business development experience, including time with BioConnect Iowa.

An advisor, hematologist/oncologist and cofounder of Highlander Health, previously principal deputy commissioner of the U.S. FDA and a leader at Flatiron Health, Duke and Verily.

Pharmaceutical and biotech industry veteran with over 25 years of experience including 12 years in executive leadership at Roche and board positions at biotech companies; previously partner at venture capital firms.

An advisor and CEO of Fogarty Innovation, a non-profit medtech incubator, with over 30 years in the medical device industry, previously CEO of Twelve Inc. and Ardian Inc.

Supports ClavystBio's C-suite leaders and manages office operations, with over a decade in high-level administrative roles at executive search and consultancy firms.

Brings clinical and investment expertise to medtech, previously on the Temasek Life Sciences team and trained in general surgery in Australia. Holds an MD from the University of New South Wales.

A board director and Managing Director of the Asia Pacific team at Temasek, previously leading healthcare and life sciences investment in EMEA and Southeast Asia, and formerly at SK Corporation.

Drives HR operations, talent management and acquisition, previously an HR Business Partner at early-stage biotech firms in Singapore.

Chairman of ClavystBio and a global healthcare and life sciences leader with three decades of experience, previously Head of Healthcare & Life Sciences at Bayshore Global Management and Global Head of Life Sciences at Temasek International.

Manages ClavystBio's collaboration space, Node 1, with over a decade of experience in diagnostic laboratory operations.

Manages ClavystBio's events and community engagement across the life sciences ecosystem, previously an Assistant Manager at Singapore's National Environment Agency.

Oversees financial functions and supports portfolio companies, previously Director (Finance) at Temasek International and an Audit Senior at KPMG.

Oversees legal aspects of ClavystBio's venture building, with nearly 20 years of legal experience including General Counsel roles at biotech and deep tech startups. Holds a law degree from Oxford and an MBA from INSEAD.

Brings over 20 years of finance, investments and capital-raising experience, including Group CFO roles at Luye Medical Group and Docquity. Holds a PhD in Finance and is a CFA Charterholder.

A board director with three decades in healthcare, including as UnitedHealth Group's Chief Scientific Officer, and founder of companies such as All Savers, Motion, Level2 and Savvysherpa.

Works on venture creation and investment with over a decade across venture capital, biotech and translational research, previously at Danaher Corporation and Heritas Capital. Holds a PhD in Biomedical Sciences (Virology) from Harvard.

A founding team member driving business development and operations, previously Vice President in Temasek's Portfolio Development Group and at PwC.

Has supported executive teams for over 15 years, previously a Talent Administrator and Coordinator at executive search firm Profile.

A board director and Senior Advisor to Rush University System for Health, previously Dean of Rush Medical College and of Duke-NUS Graduate Medical School Singapore.

Oversees development of ClavystBio's lab facility and infrastructure at Science Park, previously Technical Head for Fuchs Singapore and a founding team member of Life Science Incubator.

Supports finance and compliance matters, previously in KPMG's Governance, Risk and Advisory team and at Lightstone Ventures.

An advisor who served on BioNTech's management board from 2012 to 2024, leading fundraising, business development and commercialization, with earlier commercial roles at Pfizer and GSK.

A professional biotech board member serving on the boards of Denali Therapeutics, Guardant Health, Gritstone bio and argenx, and formerly CFO of Denali and Genentech and global head of M&A at Roche.

Venture Partner at ARCH Venture Partners and board chair of biotech companies; previously Professor at Harvard Business School and Harvard Faculty of Arts and Sciences, and President of Vertex Pharmaceuticals.

Leads ClavystBio's cybersecurity and IT strategies, with over 15 years designing secure, scalable IT frameworks across sectors. Holds a B.Comp from NUS.

Draws on a background in science, IP and venture investment for therapeutics work, previously a research scientist at A*STAR, a trainee patent attorney, and at a Singapore biotech VC. Holds a PhD from NUS.

Focuses on therapeutics investing, previously at Xora Innovation shaping its life science portfolio and at the Experimental Drug Development Centre. Holds a PhD in Biomedical Engineering from Columbia.

Works on investment and venture creation, previously at an early-stage biotech venture firm and as a life sciences commercial strategy consultant. Holds a PhD in Biomedical Engineering from Boston University.

Ed has founded and exited two media and technology businesses and is an active angel investor in the green and technology sectors.

Kieran O'Neill is a Principal at Tidal Ventures, where he invests in early-stage B2B and Vertical AI software, with an interest in regulated and asset-intensive sectors. Before venture capital, he worked in finance at KPMG, Goldman Sachs, Lloyds Bank, and Macquarie Bank, and later at managed services provider VMTech, and holds a Commerce degree in Finance and Accounting from the University of Queensland along with a Chartered Accountant qualification. He co-founded the proptech startup Hometime, where he led functions including go-to-market, finance, strategy, acquisitions, and team building.

Sonja has 26 years of experience across financial institutions in Switzerland, New York and Hong Kong, spanning corporate banking, wealth management and leadership. She holds a Bachelor's in Controlling from HWZ Zurich and is a CFA and CAIA charterholder.